"Febuxostat" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.
| Descriptor ID |
D000069465
|
| MeSH Number(s) |
D02.886.675.274 D03.383.129.708.274
|
| Concept/Terms |
TEI 6720- TEI 6720
- 6720, TEI
- TEI-6720
- TEI6720
|
Below are MeSH descriptors whose meaning is more general than "Febuxostat".
Below are MeSH descriptors whose meaning is more specific than "Febuxostat".
This graph shows the total number of publications written about "Febuxostat" by people in this website by year, and whether "Febuxostat" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Febuxostat" by people in Profiles.
-
Cardiovascular safety of febuxostat. Lancet. 2021 09 11; 398(10304):955.
-
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills et al. Ann Rheum Dis. 2022 07; 81(7):e125.
-
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma et al. Ann Rheum Dis. 2022 06; 81(6):e108.
-
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu et al. Ann Rheum Dis. 2022 07; 81(7):e123.
-
2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020 06; 72(6):879-895.
-
Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. Ann Rheum Dis. 2020 04; 79(4):529-535.
-
Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. Eur Heart J. 2019 09 21; 40(36):3046-3054.
-
Gout and chronic pain in older adults: a Medicare claims study. Clin Rheumatol. 2019 Jul; 38(7):1953-1960.
-
Any sleep is a dream far away: a nominal group study assessing how gout affects sleep. Rheumatology (Oxford). 2018 11 01; 57(11):1925-1932.
-
Gout and the risk of incident depression in older adults. Psychiatry Res. 2018 12; 270:842-844.